Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Equity Average (2016 - 2025)

Integra Lifesciences Holdings' Equity Average history spans 16 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 32.14% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, down 32.14%, while the annual FY2025 figure was $1.3 billion, 17.38% down from the prior year.
  • Equity Average for Q4 2025 was $1.0 billion at Integra Lifesciences Holdings, roughly flat from $1.0 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.8 billion in Q4 2022 and bottomed at $1.0 billion in Q3 2025.
  • The 5-year median for Equity Average is $1.6 billion (2023), against an average of $1.5 billion.
  • The largest annual shift saw Equity Average grew 16.73% in 2021 before it plummeted 32.14% in 2025.
  • A 5-year view of Equity Average shows it stood at $1.7 billion in 2021, then increased by 6.4% to $1.8 billion in 2022, then decreased by 10.25% to $1.6 billion in 2023, then decreased by 3.16% to $1.5 billion in 2024, then tumbled by 32.14% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Equity Average are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.3 billion (Q2 2025).